Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Lenalidomide maintenance for multiple myeloma.

Brower V.

Lancet Oncol. 2012 Jun;13(6):e238. Review. No abstract available.

PMID:
22833889
2.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147. Epub 2009 Jul 23.

PMID:
19626046
3.

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators..

N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.

4.

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.

Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ.

Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27. No abstract available.

5.

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.

Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M.

Cancer. 2005 Oct 1;104(7):1428-33.

6.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

7.

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.

Coman T, Bachy E, Michallet M, Socié G, Uzunov M, Bourhis JH, Lapusan S, Brebion A, Vigouroux S, Maury S, François S, Huynh A, Lioure B, Yakoub-Agha I, Hermine O, Milpied N, Mohty M, Rubio MT.

Haematologica. 2013 May;98(5):776-83. doi: 10.3324/haematol.2012.069328. Epub 2012 Nov 9.

8.

Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.

Kagoya Y, Nannya Y, Kurokawa M.

Leuk Res. 2012 Aug;36(8):1016-21. doi: 10.1016/j.leukres.2012.04.001. Epub 2012 May 10.

PMID:
22579366
9.

Hematology: Thalidomide maintenance in multiple myeloma.

Laubach JP, Richardson PG, Anderson KC.

Nat Rev Clin Oncol. 2009 Oct;6(10):565-6. doi: 10.1038/nrclinonc.2009.131. No abstract available.

PMID:
19787000
10.

Continuous treatment in multiple myeloma - ready for prime time?

Knop S.

Onkologie. 2011;34(8-9):461-6. doi: 10.1159/000331062. Epub 2011 Aug 22. Review.

PMID:
21934348
11.

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.

Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ.

Blood. 2010 Mar 25;115(12):2348-53; quiz 2560. doi: 10.1182/blood-2009-07-235531. Epub 2010 Jan 20.

12.

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM.

Haematologica. 2007 Aug;92(8):1075-82. Epub 2007 Jul 20.

13.

Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.

Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A.

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1209-22. doi: 10.1517/17425255.2012.712685. Epub 2012 Aug 3. Review.

PMID:
22862790
14.

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.

Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV.

Mayo Clin Proc. 2003 Jan;78(1):34-9.

PMID:
12528875
15.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
16.

High-dose therapy in multiple myeloma.

Harousseau JL.

Ann Oncol. 2002;13 Suppl 4:49-54. Review. No abstract available.

PMID:
12401666
17.
18.

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA.

Br J Haematol. 2008 Apr;141(1):41-51. doi: 10.1111/j.1365-2141.2008.07013.x.

PMID:
18324965
19.

Novel therapies in the treatment of multiple myeloma.

Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.

J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.

PMID:
19878638
20.

Continuous treatment with new agents for newly diagnosed multiple myeloma.

Zou Y, Sheng Z, Lu H, Yu J.

Anticancer Drugs. 2013 Jun;24(5):527-33. doi: 10.1097/CAD.0b013e32836032d5.

PMID:
23511426

Supplemental Content

Support Center